The efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis: A protocol for systematic review and meta-analysis

Abstract Background: Endometriosis ( EMS ) is one of the common diseases in women, which seriously affects the quality of life of women. Leuprorelin acetate can control the development of endometriosis, but long-term use can cause perimenopausal symptoms in women. Clinical studies have shown that Kuntai capsule combined with leuprorelin acetate is effective in the treatment of endometriosis, which can relieve perimenopausal symptoms, but it lacks of evidence-based medical evidence. Therefore, this study aims to systematically evaluate the efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis. Methods: CNKI, VIP, Wanfang, Chinese Biomedical Literature Database, PubMed, The Cochrance Library, Embase, Web of Science and other databases were searched by computer to collect randomized controlled trials of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis. The retrieval time was from the establishment of the database to February 2021. Two researchers screened the literatures and extracted the data and meta-analysis was performed using RevMan 5.3 software. Results: This study evaluated the efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis by clinical effective rate, serum sex hormone levels ( estradiol, E2 ), follicle-stimulating hormone ( FSH ), luteinizing hormone ( LH ), visual analogue scale ( VAS ), Kupperman score and incidence of adverse reactions. Conclusion: This study will provide reliable evidence-based evidence for the clinical application of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis.